Norges Bank’s Arbutus Biopharma ABUS Stock Holding History

Norges Bank’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-369,720	Closed	-$1.03M	–	2047
2019 Q4	$1.03M	Hold	369,720	–	–	﹤0.01%	2022
2019 Q3	$564K	Hold	369,720	–	–	﹤0.01%	2057
2019 Q2	$769K	Hold	369,720	–	–	﹤0.01%	2046
2019 Q1	$1.32M	Hold	369,720	–	–	﹤0.01%	2035
2018 Q4	$1.42M	Hold	369,720	–	–	﹤0.01%	2021
2018 Q3	$3.49M	Buy	+369,720	New	+$3.67M	﹤0.01%	2001

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank's ABUS Position: Q1 2020 in Review

Norges Bank sold out of Arbutus Biopharma (ABUS) in Q1 2020, closing a stake of 369,720 shares — an estimated $1.03M sold.

Norges Bank first reported a position in ABUS in Q3 2018 and held it in 6 quarters. The position peaked at $3.49M in Q3 2018. 48 funds tracked by Wall St. Rank hold ABUS as of Q1 2020.

Norges Bank reported no remaining Arbutus Biopharma position as of Q1 2020 after selling out during the quarter.
Norges Bank sold 369,720 Arbutus Biopharma shares in Q1 2020, an estimated $1.03M.
Norges Bank first reported a position in Arbutus Biopharma in Q3 2018 and held it in 6 quarters.
Norges Bank's Arbutus Biopharma position peaked at $3.49M in Q3 2018.
48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2020.

Based on Norges Bank's 13F filing for Q1 2020, filed 8 May 2020.